Genetic Polymorphisms in the Renin-angiotensin System and Cognitive Decline in Parkinson's Disease

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2021 Jul 24

PMID 34302265

Citations 3

Authors

Anna Pierzchlinska

Jaroslaw Slawek

Monika Mak

Barbara Gawronska-Szklarz

Monika Bialecka

Affiliations

Soon will be listed here.

Abstract

Background: Renin-angiotensin system (RAS) influences the central nervous system not only through its peripheral impact-the brain possesses its own local RAS. Studies showed altered RAS components in Parkinson's disease (PD) and their association with oxidative stress which may be linked to neurodegeneration and dementia. Moreover, the protective functions of RAS blockade antagonists against cognitive decline and dementia have been suggested. This study aimed to examine whether genetic variability in RAS genes correlates with cognitive decline in PD.

Methods And Results: We genotyped single nucleotide polymorphisms (SNPs) in angiotensinogen (AGT: rs699, rs4762), angiotensin II receptors (AGTR1: rs5186 and AGTR2: rs5194, rs1403543) genes, as well as insertion/deletion polymorphism in the angiotensin-converting enzyme (ACE I/D) gene in 256 PD patients, divided into three groups: without cognitive decline, with mild cognitive impairment and with PD dementia. We did not find any significant differences in the frequencies of the analysed polymorphisms in any of the groups.

Conclusions: Despite no direct correlation between the investigated polymorphisms in RAS genes and cognitive decline in PD, we believe the impact of those genotypes may be indirect, affecting RAS blockade treatment.

Citing Articles

Genetic Polymorphisms in the Gene and Associations with Cognitive Decline in Parkinson's Disease Patients.

Pierzchlinska A, Slawek J, Kwasniak-Butowska M, Malinowski D, Komaniecka N, Mak M Int J Mol Sci. 2024; 25(16).

PMID: 39201649 PMC: 11354436. DOI: 10.3390/ijms25168964.

Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease.

Angelopoulou E, Karlafti E, Georgakopoulou V, Papalexis P, Papageorgiou S, Tegos T Life (Basel). 2023; 13(2).

PMID: 36836893 PMC: 9961012. DOI: 10.3390/life13020536.

Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation.

Rahman M, Islam M, Mim S, Sultana N, Chellappan D, Dua K Oxid Med Cell Longev. 2022; 2022:8425640.

PMID: 36187336 PMC: 9519337. DOI: 10.1155/2022/8425640.

References

Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, Granado N, Moratalla R, Labandeira-Garcia J . Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol Aging. 2014; 35(7):1726-38. DOI: 10.1016/j.neurobiolaging.2014.01.017. View

Deschepper C, Bouhnik J, Ganong W . Colocalization of angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain. Brain Res. 1986; 374(1):195-8. DOI: 10.1016/0006-8993(86)90411-7. View

Stornetta R, Guyenet P, Lynch K . Astrocytes synthesize angiotensinogen in brain. Science. 1988; 242(4884):1444-6. DOI: 10.1126/science.3201232. View

Konings C, Kuiper M, Bergmans P, Grijpma A, Van Kamp G, Wolters E . Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin Chim Acta. 1994; 231(1):101-6. DOI: 10.1016/0009-8981(94)90259-3. View

Zawada W, Mrak R, Biedermann J, Palmer Q, Gentleman S, Aboud O . Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun. 2015; 3:9. PMC: 4359535. DOI: 10.1186/s40478-015-0189-z. View

Rodriguez-Pallares J, Rey P, Parga J, Munoz A, Guerra M, Labandeira-Garcia J . Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis. 2008; 31(1):58-73. DOI: 10.1016/j.nbd.2008.03.003. View

Mertens B, Vanderheyden P, Michotte Y, Sarre S . The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst. 2009; 11(1):49-56. DOI: 10.1177/1470320309347789. View

van Muiswinkel F, de Vos R, Bol J, Andringa G, Jansen Steur E, Ross D . Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging. 2004; 25(9):1253-62. DOI: 10.1016/j.neurobiolaging.2003.12.010. View

Lu J, Wu L, Jiang T, Wang Y, Zhao H, Gao Q . Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson's disease in CATH.a cells. Neurotoxicol Teratol. 2014; 47:16-24. DOI: 10.1016/j.ntt.2014.11.004. View

10.

Reardon K, Mendelsohn F, Chai S, Horne M . The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust N Z J Med. 2000; 30(1):48-53. DOI: 10.1111/j.1445-5994.2000.tb01054.x. View

11.

Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia J . Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J Neurosci Res. 2005; 81(6):865-73. DOI: 10.1002/jnr.20598. View

12.

Zhuang S, Wang H, Li J, Wang H, Wang X, Xing C . Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis. Neurosci Lett. 2016; 624:53-61. DOI: 10.1016/j.neulet.2016.05.003. View

13.

Zhuang S, Wang H, Wang X, Li J, Xing C . The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: A meta-analysis. J Clin Neurosci. 2016; 33:32-38. DOI: 10.1016/j.jocn.2016.02.036. View

14.

Udovin L, Otero-Losada M, Bordet S, Chevalier G, Quarracino C, Capani F . Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database. Parkinsonism Relat Disord. 2021; 86:34-37. DOI: 10.1016/j.parkreldis.2021.03.007. View

15.

Zhu K, van Hilten J, Marinus J . Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat Disord. 2014; 20(9):980-5. DOI: 10.1016/j.parkreldis.2014.06.006. View

16.

Anang J, Gagnon J, Bertrand J, Rios Romenets S, Latreille V, Panisset M . Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology. 2014; 83(14):1253-60. PMC: 4180482. DOI: 10.1212/WNL.0000000000000842. View

17.

Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sorensen P . Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60(3):387-92. DOI: 10.1001/archneur.60.3.387. View

18.

Huertas I, Jesus S, Garcia-Gomez F, Lojo J, Bernal-Bernal I, Bonilla-Toribio M . Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease. PLoS One. 2017; 12(4):e0175560. PMC: 5388496. DOI: 10.1371/journal.pone.0175560. View

19.

Song G, Lee Y . The insertion/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson's disease: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2014; 16(2):434-42. DOI: 10.1177/1470320313495909. View

20.

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View